Hello, everyone, and how are you today? A bright sun is hovering over the Pharmalot corporate campus this morning, where we are busy organizing our priorities and already planning for next week. Nothing like trying to get a head start, yes? This calls, of course, for a cup of stimulation, so please join us. Meanwhile, here are a few tidbits from around the world. Hope your day goes well...
Lilly And Boehringer Diabetes Med Gets European OK (Associated Press)
United Therapeutics Misses Study Goal (Bloomberg News)
Alexa Life Sciences Rejects Offer From Paladin Labs (Pharma Times)
FDA OKs Botox For Loss Of Bladder Control (Reuters)
NICE Says No To Bristol For Second-Line Orencia Use (InPharm)
Charles River Unifies Research And Preclinical Services Units (Contract Pharma)
EDITOR'S NOTE: Please check this post for updates throughout the morning
1 Comment
The Charles River Research Model Service is probably not well known but this is where researchers obtain animal models of human disease to test out investigational new drugs fresh out of the lab. CR has been breeding these models since I was in school. The consolidation of this business with the preclinical is a clear signal to me that drug companies today are less willing to invest in drug discovery. This may well have a trickle up effect to the rest of preclinical and clinical research.